Atea Pharmaceuticals (AVIR) Gains as COVID Drug Highlighted by NYT
- S&P 500 edges down on virus woes, slowing economy
- 'Becoming JP Morgan of the Future': Square (SQ) Dips on Deal to Acquire BNPL Afterpay For $29B in Stock, Benefits Outweigh High Price Says Analyst
- Oil falls over 3% on concerns over demand and OPEC supply boost
- ON Semiconductor (ON) Surges on Strong Q2 Results and Q3 Outlook
- Dollar wavers on dovish Fed tone, mixed economic outlook
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Atea Pharmaceuticals Inc. (NASDAQ: AVIR) gains intra-day as New York Times discusses 'A pill to treat COVID-19', which highlights the company's AT-527.
From the article:
"One of the drugs the government is considering is AT-527, developed by Atea Pharmaceuticals. The compound has already proven safe and effective as a treatment for hepatitis C, and early studies suggested it might also work against Covid-19. Roche has partnered with Atea to test it in people, and the companies are currently running a late-stage clinical trial."
Shares of AVIR are up 6% intra-day.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Autolus Therapeutics' (AUTL) Deal with MRNA - Broad Validation of the Platform - Analyst
- Rocket Companies (RKT) Climbs 6%
- AMD (AMD) Shares Outperform, Up 3.5%
Create E-mail Alert Related CategoriesFDA, Momentum Movers, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!